Saudi Arabia Cancer Immunotherapy Market Report 2022 to 2030

Saudi Arabia Cancer Immunotherapy Market Analysis

$ 3999

Saudi Arabia's cancer immunotherapy market is expected to witness growth from $1.9 Bn in 2022 to $3.7 Bn in 2030 with a CAGR of 8.6% for the forecasted year 2022 to 2030. The rising demand for immunotherapy treatments and rapid approvals for immunotherapy drugs in Saudi Arabia is responsible for the growth of the market. The Saudi Arabia cancer immunotherapy market is segmented by type, application, and end user. Jamjoom Pharma, Damman Pharma, and Merck are the major players in the Saudi Arabia cancer immunotherapy market.

ID: IN10SAPH032 CATEGORY: Pharmaceuticals GEOGRAPHY: Saudi Arabia AUTHOR: Dr. Parul Choudhary

Buy Now

Saudi Arabia Cancer Immunotherapy Market Executive Analysis

The Saudi Arabia cancer immunotherapy market size is at around $1.9 Bn in 2022 and is projected to reach $3.7 Bn in 2030, exhibiting a CAGR of 8.6% during the forecast period. With a total approved spending of $297 Bn, projected receipts of $301 Bn, and an estimated surplus of $4 Bn (0.4% of GDP), the annual budget for the fiscal year 2023 was approved by the Council of Ministers in Saudi Arabia. By the end of Q2 2022, there were 4.5 Mn beneficiaries, therefore the virtual clinic's services were being expanded. operating the first 20 specialized medical rehabilitation clinics and connecting them to the "Mawid" System in the regions and communities with the intention of easing access to the service and enhancing the standard of services.

In Saudi Arabia, there were almost 13.65 thousand instances of breast cancer with a 5-year prevalence in 2020. In Saudi Arabia, there were around 43.4 thousand cases of cancer with a 5-year prevalence that year, compared to 39.2 thousand cases among males.

Numerous patients' aggressive cancers have been effectively treated with immunotherapy to make them treatable conditions. As a result, immunotherapy has drawn a lot of attention globally, and Saudi Arabia was no exception. Five immune checkpoint inhibitors have been approved by the FDA out of the eight that have regulatory approval. Yervoy (ipilimumab), Nivolumab (Opdivo), Pembrolizumab (Keytruda), atezolizumab (Tecentriq), and avelumab (Bavencio) are examples of immune checkpoint inhibitors. Additionally, only KYMRIAHTM (tisagenlecleucel) has been approved by the FDA out of the five CAR T cell therapy treatments that have gained regulatory approval. Only 3 of the 6 experimental clinical trials that were carried out in Saudi Arabia to assess immunological checkpoint inhibitors are still active.

Saudi Arabia Cancer Immunotherapy Market Analysis

Market Dynamics

Market Growth Drivers

Immunotherapy is becoming more and more popular in Saudi Arabia as more patients and medical professionals learn about it and its potential advantages. A possible alternative to conventional cancer therapies like chemotherapy and radiation therapy is immunotherapy. The development and commercialization of cancer immunotherapy treatments have received backing from the Saudi Arabian government, which has assisted in the market's expansion. New cancer medications are now approved more swiftly thanks to the Saudi Food and Drug Authority (SFDA)'s (SFDA) streamlining of the procedure. Saudi Arabia has recently made large investments in healthcare, including the construction of new hospitals and healthcare facilities. The need for sophisticated cancer therapies, such as immunotherapy, is being driven by this investment. These factors are responsible for the expansion of Saudi Arabia's cancer immunotherapy market.

Market Restraints

The high cost of cancer immunotherapy treatments may make them out of reach for many Saudi patients. For both patients and healthcare providers, the high cost of treatment presents a significant problem and may be a growth inhibitor for the industry. A lot of patients may not be able to afford cancer immunotherapy therapies in Saudi Arabia due to the country's restricted funding potential. For pharmaceutical businesses trying to advertise their goods in Saudi Arabia, this is a significant obstacle and can limit the growth of the Saudi Arabia cancer immunotherapy market.

Competitive Landscape

Key Players

Tabuk (SAU)
SPIMACO (SAU)
Hikma (SAU)
Jamjoom Pharma (SAU)
Damman Pharma (SAU)
Merck
Janssen Global Services
Seattle Genetics
Printegra
Gristone Oncology
Pfizer

Healthcare Policies and Regulatory Landscape

Through the Saudi Arabian Cooperative Health Insurance (SACHI), the country's national health insurance program, cancer sufferers in Saudi Arabia are eligible for medical coverage and reimbursement for cancer treatments. Immunotherapy and other medical procedures are covered by SACHI along with other medical services. However, Saudi Arabia's cancer treatment reimbursement regulations can be intricate and can change according to the type of therapy used and the patient's insurance coverage. For instance, while some cancer therapies may be completely covered, others can have a patient-paid copayment. The kinds of cancer therapies that are covered by SACHI could also be restricted. For instance, certain immunotherapy procedures might not be covered or might only be covered for particular cancer types.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Cancer Immunotherapy Segmentation

By Type (Revenue, USD Billion):

Monoclonal Antibodies
Cancer Vaccines
Checkpoint Inhibitors
Immunomodulators
PD-1/PD-L1
CTLA-4

By Application (Revenue, USD Billion):

Lung Cancer
Breast Cancer
Head and Neck Cancer
Prostate Cancer
Colorectal Cancer
Melanoma
Others

By End User (Revenue, USD Billion):

Hospitals
Clinics
Ambulatory Surgical Centers (ASCs)
Cancer Research Centers

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.

To request a free sample copy of this report, please complete the form below.

We value your inquiry and offer free customization with every report to fulfil your exact research needs.

Yes, I have read the privacy policy

Jamjoom Pharma, Damman Pharma, and Merck are the major players in the Saudi Arabia cancer immunotherapy market.

The Saudi Arabia cancer immunotherapy market is expected to grow from $1.9 Bn in 2022 to $3.7 Bn in 2030 with a CAGR of 8.6% for the forecasted year 2022-2030.

The Saudi Arabia cancer immunotherapy market is segmented by type, application, and end user.